Daniela Voskova

879 total citations
19 papers, 515 citations indexed

About

Daniela Voskova is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Daniela Voskova has authored 19 papers receiving a total of 515 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Hematology, 7 papers in Genetics and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Daniela Voskova's work include Acute Myeloid Leukemia Research (14 papers), Lymphoma Diagnosis and Treatment (6 papers) and Hematopoietic Stem Cell Transplantation (5 papers). Daniela Voskova is often cited by papers focused on Acute Myeloid Leukemia Research (14 papers), Lymphoma Diagnosis and Treatment (6 papers) and Hematopoietic Stem Cell Transplantation (5 papers). Daniela Voskova collaborates with scholars based in Austria, Germany and Czechia. Daniela Voskova's co-authors include Susanne Schnittger, Claudia Schoch, Torsten Haferlach, Wolfgang Kern, Wolfgang Hiddemann, Richard Greil, Alois Lang, Michael Pfeilstöcker, Christoph Tinchon and Sonja Burgstaller and has published in prestigious journals such as Blood, Cancer Research and Journal of Hematology & Oncology.

In The Last Decade

Daniela Voskova

19 papers receiving 496 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniela Voskova Austria 9 459 190 170 145 58 19 515
María José Calmuntia Spain 6 466 1.0× 240 1.3× 185 1.1× 91 0.6× 45 0.8× 9 502
Evelyn Zellmeier Germany 9 524 1.1× 133 0.7× 234 1.4× 193 1.3× 27 0.5× 16 552
Daniela Cilloni Italy 6 581 1.3× 242 1.3× 259 1.5× 255 1.8× 28 0.5× 11 649
P Lemež Czechia 10 436 0.9× 276 1.5× 174 1.0× 96 0.7× 62 1.1× 27 575
Mirjam Klaus Greece 6 343 0.7× 111 0.6× 165 1.0× 128 0.9× 22 0.4× 10 413
Laurence Baranger France 12 244 0.5× 114 0.6× 110 0.6× 104 0.7× 63 1.1× 19 362
Madlen Jentzsch Germany 13 405 0.9× 132 0.7× 111 0.7× 104 0.7× 17 0.3× 61 469
SL George United States 9 457 1.0× 264 1.4× 169 1.0× 169 1.2× 43 0.7× 14 597
Maria Paz Queipo De Llano Spain 6 384 0.8× 146 0.8× 211 1.2× 113 0.8× 17 0.3× 13 441

Countries citing papers authored by Daniela Voskova

Since Specialization
Citations

This map shows the geographic impact of Daniela Voskova's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniela Voskova with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniela Voskova more than expected).

Fields of papers citing papers by Daniela Voskova

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniela Voskova. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniela Voskova. The network helps show where Daniela Voskova may publish in the future.

Co-authorship network of co-authors of Daniela Voskova

This figure shows the co-authorship network connecting the top 25 collaborators of Daniela Voskova. A scholar is included among the top collaborators of Daniela Voskova based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniela Voskova. Daniela Voskova is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Rinnerthaler, Gabriel, Simon Peter Gampenrieder, Christoph Tinchon, et al.. (2021). Abstract PS12-21: First-line treatment of hormone receptor positive metastatic breast cancer (MBC) in everyday practice: Results from the Austrian AGMT_MBC-Registry. Cancer Research. 81(4_Supplement). PS12–21. 1 indexed citations
2.
Huemer, Florian, Lukas Weiß, Daniel Neureiter, et al.. (2018). Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia. Wiener klinische Wochenschrift. 130(3-4). 115–125. 1 indexed citations
3.
4.
Fuchs, David, et al.. (2017). Torsade de pointes in a patient with severe hypercalcaemia and multiple myeloma.. PubMed. 75(5). 208–210. 1 indexed citations
5.
Pleyer, Lisa, Sonja Burgstaller, Michael Girschikofsky, et al.. (2014). Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group. Annals of Hematology. 93(11). 1825–1838. 62 indexed citations
6.
Fiegl, Michael, Reinhard Stauder, Michael Steurer, et al.. (2013). Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients. Annals of Hematology. 93(2). 267–277. 12 indexed citations
7.
8.
Pleyer, Lisa, Reinhard Stauder, Sonja Burgstaller, et al.. (2013). Azacitidine in patients with WHO-defined AML – Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group. Journal of Hematology & Oncology. 6(1). 32–32. 44 indexed citations
9.
Fiegl, Michael, Florian Falkner, Michael Steurer, et al.. (2011). Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients. Annals of Hematology. 90(9). 1083–1091. 7 indexed citations
10.
Voskova, Daniela, Susanne Schnittger, Claudia Schoch, Torsten Haferlach, & Wolfgang Kern. (2006). Use of five-color staining improves the sensitivity of multiparameter flow cytomeric assessment of minimal residual disease in patients with acute myeloid leukemia. Leukemia & lymphoma. 48(1). 80–88. 21 indexed citations
11.
Kern, Wolfgang, Daniela Voskova, Claudia Schoch, Susanne Schnittger, & Torsten Haferlach. (2005). Multivariate Analysis of Prognostic Impact of Flow Cytometrically Determined Minimal Residual Disease in Patients with Acute Myeloid Leukemia.. Blood. 106(11). 2371–2371. 1 indexed citations
12.
Kern, Wolfgang, Daniela Voskova, Susanne Schnittger, et al.. (2004). Four-fold staining including CD45 gating improves the sensitivity of multiparameter flow cytometric assessment of minimal residual diseasein patients with acute myeloid leukemia. The Hematology Journal. 5(5). 410–418. 18 indexed citations
13.
Voskova, Daniela, Claudia Schoch, Susanne Schnittger, et al.. (2004). Stability of leukemia‐associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: Comparison with cytomorphologic, cytogenetic, and molecular genetic findings. Cytometry Part B Clinical Cytometry. 62B(1). 25–38. 59 indexed citations
14.
Kern, Wolfgang, Daniela Voskova, Claudia Schoch, et al.. (2004). Determination of Minimal Residual Disease in Patients with Acute Myeloid Leukemia by Multiparameter Flow Cytometry: Prognostic Impact at Different Checkpoints.. Blood. 104(11). 400–400. 4 indexed citations
15.
Kern, Wolfgang, Claudia Schoch, Torsten Haferlach, et al.. (2004). Minimal Residual Disease in Patients with Acute Myeloid Leukemia Quantified by Multiparameter Flow Cytomety and Quantitative RT-PCR Is an Independent Prognostic Parameter.. Blood. 104(11). 319–319. 4 indexed citations
16.
17.
Kern, Wolfgang, Daniela Voskova, Claudia Schoch, et al.. (2004). Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia.. PubMed. 89(5). 528–40. 53 indexed citations
18.
19.
Voskova, Daniela, et al.. (2003). Leukemic cells and aberrant phenotypes in acute leukemia patients: a flow cytometry analysis.. PubMed. 50(6). 422–7. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by María José Calmuntia Breakdown of academic impact, for papers by Evelyn Zellmeier Breakdown of academic impact, for papers by Daniela Cilloni Breakdown of academic impact, for papers by P Lemež Breakdown of academic impact, for papers by Mirjam Klaus Breakdown of academic impact, for papers by Laurence Baranger Breakdown of academic impact, for papers by Madlen Jentzsch Breakdown of academic impact, for papers by SL George Breakdown of academic impact, for papers by Maria Paz Queipo De Llano
Rankless by CCL
2026